Evotec Neurosciences in-licenses compound

Published: 24-Mar-2005

Evotec OAI's soon to be 100% owned subsidiary, Evotec Neurosciences (ENS), has in-licensed a compound from an unnamed third party that has safely completed a Phase I clinical trial.


Evotec OAI's soon to be 100% owned subsidiary, Evotec Neurosciences (ENS), has in-licensed a compound from an unnamed third party that has safely completed a Phase I clinical trial.

ENS aims to reposition the compound in a CNS (central nervous system) indication different from that for which it was originally developed. To test the repositioning hypothesis, the company is planning a small proof-of-concept trial. If successful, the compound may be further developed.

The in-licensing transaction does not have an immediate material impact on the profit and loss statement and cash position of ENS and Evotec OAI, and ENS is not obliged to make any future milestone payments or conduct any trials beyond the initial trial.

You may also like